Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medroxyprogesterone Clear all
Completed Phase 2 Interventional

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

NCT00033358
View directory record Official record
Conditions
Endometrial Cancer
Interventions
medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824
View directory record Official record
Conditions
Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

NCT02353247
View directory record Official record
Conditions
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Interventions
Norethindrone acetate
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Effects of Oral Contraceptive Pills Versus Metformin

NCT03229057
View directory record Official record
Conditions
PCOS
Interventions
OCP + Metformin, OCP + Placebo, Metformin + Placebo
Drug
Lead sponsor
Anuja Dokras
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
View directory record Official record
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
View directory record Official record
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sexual Health Texting Intervention to Support Adolescent Females

NCT02419690
View directory record Official record
Conditions
Teen Sexual Health
Interventions
text message intervention
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Acting Reversible Contraception

NCT01299116
View directory record Official record
Conditions
Contraception
Interventions
DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
916 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 9:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods

NCT00253019
View directory record Official record
Conditions
Contraception
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

NCT00543634
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA, Provera 10 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00064025
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 21, 2026, 9:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Modulation of Immunity by Hormonal Contraceptives

NCT02011711
View directory record Official record
Conditions
Contraception
Interventions
Not listed
Lead sponsor
Thomas L. Cherpes
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

NCT04682353
View directory record Official record
Conditions
Contraception
Interventions
TV-46046, Depo-subQ Provera
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Early Phase 1 Interventional Results available

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

NCT03018249
View directory record Official record
Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Interventions
Entinostat, Hysterectomy, Laboratory Biomarker Analysis, Medroxyprogesterone Acetate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
234
States / cities
Hot Springs, Arkansas • Concord, California • Walnut Creek, California + 158 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 9:30 AM EDT
Completed No phase listed Observational

Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

NCT02657148
View directory record Official record
Conditions
Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions
Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 21, 2026, 9:30 AM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Meaningful Use of Technology to Improve Health Care Delivery

NCT01641380
View directory record Official record
Conditions
Contraceptive Behavior
Interventions
Text Messaging Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 3 Interventional

Heart and Estrogen-Progestin Replacement Study (HERS)

NCT00319566
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contraception Initiation Feasibility in the Pediatric ED

NCT03559634
View directory record Official record
Conditions
Contraception, Contraception Behavior
Interventions
Intervention Group, Control Group
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 21 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 21, 2026, 9:30 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera

NCT07148999
View directory record Official record
Conditions
Infertility (IVF Patients)
Interventions
Opt-IVF, Control
Combination Product · Other
Lead sponsor
Urmila DIwekar
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 21, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

NCT00139685
View directory record Official record
Conditions
Contraception, Bone Density
Interventions
Depo-Provera Contraceptive Injection - DP150CI
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 18 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 21, 2026, 9:30 AM EDT